Great Bay Bio is proud to announce a collaboration with Eureka Therapeutics to co-develop a cutting-edge specialized AI model for antibody discovery. Leveraging GBB’s advanced artificial intelligence capabilities and Eureka’s expertise in cancer-specific targets, this collaboration is poised to accelerate the development of next-generation, highly precise antibody therapeutics targeting solid tumors and other challenging diseases, setting a new benchmark in biopharmaceutical innovation.

This partnership is more than a joint development — it represents a bold step toward transforming the way the world discovers and engineers antibody drugs. Together, GBB and Eureka are not only accelerating timelines but reshaping the landscape of cancer immunotherapy through AI, setting a new benchmark for the future of biopharmaceutical innovation.

About Eureka Therapeutics

Eureka Therapeutics is a clinical-stage biopharmaceutical company developing transformative technology platforms that can access cancer-specific targets and harness the evolutionary power of T cells for the treatment of solid tumors and other malignancies.

About Great Bay Bio

Great Bay Bio, headquartered in HKSTP, is a biotech company that drives drug development using cutting-edge technologies such as AI, big data mining, and automation. GBB adheres to the corporate vision of "Global Bioprocessing Made Simpler and More Efficient," and aims to address the challenges of long timelines, high costs, and low success rates in drug development, with a long-term goal of enhancing human life, health, and value.